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The prognosis of patients with advanced hepatocellular carcinoma (HCC) is very poor. 
The outcome of these patients is particularly bleak when the disease is complicated by 
portal vein tumor thrombosis (PVTT), since the increased portal pressure often causes 
serious gastrointestinal bleedings. Before the introduction of sorafenib (SOR), a tyrosine 
kinase inhibitor, no effective treatment was available for patients with advanced disease. 
SOR is now considered the standard treatment even for patients with tumor thrombosis, 
although the well-known interference between tyrosine kinase inhibitors and the 
coagulation pathway calls for caution against their use in this setting. Here, we report 
the case of a 74-year-old male patient with advanced HCC and PVTT treated with 
sunitinib (SUN), another multikinase inhibitor. During the third cycle, our patient 
experienced a life-threatening hematemesis with hemorrhagic shock that required 
intensive care treatment and SUN discontinuation. However, he completely recovered, 
and the PET/CT scan performed 1 year after the adverse effect demonstrated no evidence 
of the tumor together with portal vein recanalization. The short course of SUN causing 
both tumor response and gastrointestinal bleeding warrants further studies on the  
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effectiveness of SUN in this setting as well as on the duration of treatment with 
multikinase inhibitors in patients with tumor thrombosis. 
 
Introduction 
Portal vein tumor thrombosis (PVTT) is one of the worst prognostic factors in patients 
with hepatocellular carcinoma (HCC) originating from liver cirrhosis. It can be observed 
in about 30% of HCC patients [1, 2], and the average survival of these patients after the 
diagnosis is very poor (2.7–4.0 months) [3]. Death is often due either to a progressive 
increase in portal pressure, resulting in gastrointestinal bleeding, or to the decrease in 
portal vein flow leading to ascites, jaundice, encephalopathy and liver failure. Until a few 
months ago, best supportive care was considered a reasonable choice for patients with 
such a critical prognosis, since transarterial chemoembolization entails a high risk of 
ischemic damage [4] and chemotherapy was largely ineffective. Some authors reported 
high survival rates in patients treated with a combination of transarterial 
chemoembolization and surgery with thrombectomy [5], but this procedure may be used 
only in highly selected patients. 
Since sorafenib (SOR) has been shown to improve survival in patients with advanced 
HCC [6], this drug has become the standard treatment even for patients whose disease 
was complicated by PVTT. So far, however, there is no clear evidence concerning the 
effect of SOR in this subset of patients and their outcome. On the other hand, the well-
known interference between tyrosine kinase inhibitors and the coagulation pathway [7] 
calls for caution against their use in this setting. 
Here, we describe a case of multifocal HCC with PVTT showing an unexpected 
favorable outcome after a short course of sunitinib (SUN), a tyrosine kinase inhibitor 
which is currently under investigation for use in the treatment of intermediate-advanced 
HCC. 
Case Report 
A 72-year-old male patient affected by chronic HCV-related hepatitis underwent percutaneous 
alcohol injection for a nodule of the sixth segment of the liver. Two years later, an abdominal CT scan 
demonstrated a massive thrombus involving the main portal vein and its branches, with infiltrative (not 
evaluable according to RECIST) neoplastic pattern of the sixth segment (fig. 1a1–a3). Histologic and 
cytologic examination of a needle biopsy of the infiltrative lesion and a fine needle aspiration of the 
portal vein thrombus demonstrated a poorly differentiated trabecular HCC with tumor thrombosis. 
Child-Pugh score was A6 with MELD score 10, and the tumor stage was BCLC-C. Serum albumin, 
ammonium, creatinine and coagulation parameters were normal; blood chemistry documented only a 
slight increase in transaminases (ALT 66 IU/l and AST 57 IU/l), alkaline phosphatase (377 IU/l) and γ-
glutamyltransferase (122 IU/l). Blood count showed mild anemia (hemoglobin 11.2 g/dl) and 
thrombocytopenia (84 × 10
3/mm
3). There was no ascites, and serum α-fetoprotein was 3 ng/ml. No 
distant metastases were detected on a whole-body CT scan and bone scintigraphy, and upper endoscopy 
showed no esophageal varices. 
18F-Fluorodeoxyglucose (FDG) PET-CT showed 
18F-FDG uptake (fig. 2a) 
in the sixth segment of the right lobe (standard uptake value, SUV, 4.6) and also at the liver hilum (SUV 
3.1.). 
The patient was enrolled in a phase II study (EudraCT No. 2005-005732-27) with SUN (50 mg/die) 
on a standard 4-week-on/2-week-off regimen. After the first cycle, a 25% dose reduction was required 
because of grade III thrombocytopenia. The other reported toxicities were grade II fatigue, mild  
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hypertension, grade I nausea and a cutaneous rash. The PET-CT scan performed after the first cycle 
showed metabolic stabilization of the disease according to EORTC criteria [8], with a reduction in SUV 
<15% (4.1 vs. 4.6 at the sixth segment and 2.8 vs. 3.1 at the liver hilum). A CT scan performed after the 
second cycle confirmed a stable disease.  
Ten days after the start of the third cycle, the patient experienced severe loss of appetite and nausea, 
followed, in a few hours, by copious hematemesis and hemorrhagic shock. Emergency gastroscopy 
revealed hemorrhagic gastritis. Prompt treatment with plasma substitutes, blood transfusions, 
vasoactive drugs and antibiotics was started, and SUN was discontinued.  
The patient recovered and his clinical status constantly improved in the following weeks without any 
further treatment. Twelve months after the hematemesis (April 2009) episode, a PET-CT scan did not 
indicate any sign of the tumor (complete response according to EORTC criteria; fig. 2b). In a CT scan 
performed at the same time, the left branch of the portal vein was completely canalized but enlarged, 
whereas the main trunk and the right branch were substituted by fibrotic, cord-like tissue, and collateral 
vessels were present at the liver hilum. No signs of HCC were detectable in the liver parenchyma (fig. 
1b1–b3). The Child-Pugh score was A5 and the MELD score 9.  
Conclusions 
The introduction of SOR in the treatment of advanced HCC has resulted in great 
enthusiasm since it was the first drug to beneficially affect the survival rate in this setting, 
although some issues have been raised concerning cost-effectiveness and patient selection. 
However, the possibility of increasing survival even for <3 months may be considered the 
beginning of a new era in the treatment of HCC, and it has given incentive to evaluate 
other agents and to target alternative pathways.  
SUN is a multikinase inhibitor, but it shares the mechanism of action of SOR only 
partially, because of its stronger inhibition of VEGFR-related pathways due to an 
interaction both with VEGFR1 and VEGFR2 [9]. In the case reported here, a complete 
metabolic response and a partial morphologic response were achieved, lasting >1 year 
despite the interruption of SUN at the beginning of the third cycle. This excellent 
outcome was accompanied by re-canalization of PVTT and liver function improvement. 
The response seemed predicted by SUV reduction on the PET-CT scan. Although the 
sensitivity of 
18F-FDG-PET for HCC is about 50% and it is well known that 
18F-FDG 
uptake is associated with tumor differentiation [10], 
18F-FDG uptake is significantly 
higher in poorly differentiated HCC and may be a good predictor of outcome in these 
patients [11].  
A clinical response according to EORTC criteria and RECIST is very rare in HCC. In 
the SHARP study [6], only 2 partial responses were observed in 299 patients treated with 
SOR. However, it must be considered that in our patient treatment was complicated by a 
potentially life-threatening side effect which required hospitalization in an intensive care 
unit. Even if gastrointestinal bleeding is a very common adverse event in PVTT patients, 
we cannot exclude a relationship between treatment and the complication due to the 
interaction between SUN and the coagulation pathway. This case clearly stresses the 
narrow therapeutic window of multikinase inhibitors in HCC originating from liver 
cirrhosis. The same mechanism of action that interferes with tumor growth might affect 
the liver vasculature already impaired by cirrhosis. The brief exposure to SUN needed in 
our patient to obtain both tumor response and gastrointestinal bleeding suggests further 
studies on the effectiveness of SUN in this setting as well as on the duration of treatment 
with multikinase inhibitors in HCC.  
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Although SUN treatment in advanced HCC has been evaluated only in a few phase-II 
studies and resulted in poor outcome [12, 13], our case report may attract further interest 
in this drug, since the response rate with SOR is very low despite its survival benefit; 
moreover, no specific evaluation of patients with PVTT was made. Targeting a different 
set of tyrosine kinase receptors, including VEGFR1 and VEGFR2, PDGFR and c-KIT, 
SUN, or other multikinase inhibitors, might exert a different effect both on cancer cells 
and the coagulation pathway compared to SOR, which mainly interferes with the 
Raf/MEK/ERK pathway [14].  
In conclusion, in this patient with advanced HCC, SUN was highly effective not only in 
terms of metabolic and morphologic responses, but also of PVTT recanalization. As far as 







Fig. 1. CT scan at baseline (a1–a3) and 1 year later (b1–b3).  
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Fig. 2. PET-CT scan at baseline (a) and 1 year later (b). 
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